AustralianSuper Pty Ltd Sells 343,966 Shares of Gilead Sciences, Inc. $GILD

AustralianSuper Pty Ltd decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% in the third quarter, Holdings Channel reports. The firm owned 3,034,089 shares of the biopharmaceutical company’s stock after selling 343,966 shares during the period. Gilead Sciences comprises about 1.5% of AustralianSuper Pty Ltd’s portfolio, making the stock its 9th largest position. AustralianSuper Pty Ltd’s holdings in Gilead Sciences were worth $336,784,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC raised its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences during the third quarter valued at about $26,000. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $27,000. Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $30,000. Finally, Putney Financial Group LLC boosted its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
• Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
• Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
• Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
• Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale

Gilead Sciences Price Performance

Shares of GILD opened at $139.72 on Thursday. The company has a market capitalization of $173.35 billion, a P/E ratio of 21.66, a P/E/G ratio of 0.74 and a beta of 0.33. The business’s 50-day moving average is $124.76 and its two-hundred day moving average is $119.24. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $141.71.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the sale, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 247,397 shares of company stock valued at $31,986,612 in the last three months. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on GILD shares. BMO Capital Markets upped their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday. Wolfe Research reissued an “outperform” rating and set a $150.00 price objective on shares of Gilead Sciences in a report on Monday, December 15th. Citigroup upped their target price on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, UBS Group boosted their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $135.36.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.